Covid 19 Research using Clinical Trials (Home Page)
Vehicle ControlWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
Correlated MeSH Terms (6)
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with
mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are
hospitalized and require supplemental oxygen therapy with or without mechanical ventilation.
It is thought that COVID-19 activates the complement system, part of the immune system that
responds to infection or tissue damage, and increases inflammation in the lungs. APL-9 has
been designed to inhibit or block activation of part of the complement pathway, and
potentially reduce inflammation in the lungs.
Part 1 of the study is open-label to evaluate safety; all participants will receive APL-9
plus standard of care. Part 2 of the study is double-blind, randomized; participants will
receive either APL-9 or the vehicle-control plus standard of care.
Primary Outcomes
Measure: Cumulative incidence of treatment-emergent serious adverse events and treatment-emergent adverse events. Time: Day 1 through Day 21
Secondary Outcomes
Measure: Hospital length of stay Time: Day 1 through Day 21
Measure: Any cause of mortality Time: Day 1 through day 51
Measure: SOFA score Time: Day 1 through day 21
Measure: Total duration of mechanical ventilation Time: Day 1 through day 21
Measure: Total duration of oxygen therapy Time: Day 1 through day 21
No related HPO nodes (Using clinical trials)